Edimer Pharmaceuticals

Edimer Pharmaceuticals focuses on developing innovative therapies to meet unmet medical needs, primarily in the realm of rare diseases. The company is dedicated to improving patient outcomes through its specialized medications. Edimer Pharmaceuticals, founded in 2009, is based in Cambridge, US. The company specializes in developing therapies for rare diseases.

In July 2013, Edimer completed a Series B financing round, raising USD 9. 79 mn led by New Enterprise Associates, with participation from Sanofi Ventures, Third Rock Ventures, and Vi Partners. The company has engaged in a total of 3 deals to date, with a current valuation of USD 32. 11 mn.

The founder’s history and further details about subsidiaries are not available. Edimer Pharmaceuticals offers a range of pharmaceutical products primarily focused on innovative therapies aimed at addressing unmet medical needs in various therapeutic areas. The company's core offerings include specialty medications that target specific conditions and improve patient outcomes. These products are designed for diverse end-use cases, such as treating rare diseases and enhancing the quality of life for patients suffering from complex health issues.

The company serves a wide array of clients, including healthcare providers, hospitals, and specialty pharmacies, with end users comprising patients requiring specialized care. The geographical markets for these products extend beyond local boundaries, targeting regions such as North America and Europe, where there is a significant demand for advanced therapeutic solutions. Revenue generation for Edimer Pharmaceuticals is structured around direct-to-consumer sales as well as partnerships with healthcare providers and specialty pharmacies. The company engages in business transactions through a model that includes the sale of its flagship therapeutic products, which may involve pricing plans based on volume purchases or subscription services for healthcare professionals.

Clients typically place orders directly through the company's platform or via authorized distributors, ensuring a streamlined procurement process. Revenue is driven by the demand for specialized medications, which are key to addressing specific medical conditions, aligning with the company's mission to deliver effective healthcare solutions. The established pricing framework reflects the value provided by these tailored therapies, fostering long-term relationships with healthcare providers and other stakeholders in the industry. Edimer Pharmaceuticals plans to utilize the funds from the USD 9.

79 mn Series B financing led by New Enterprise Associates in July 2013 to support the development of new therapeutic products targeted at rare diseases. The company is also exploring expansion into European markets to meet growing demand for its innovative treatments. This strategic initiative aims to enhance its geographical presence and drive revenue growth, ensuring that the company can address the needs of patients in diverse regions. Specific timelines for product launches and market entry are not disclosed.